decrease

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:54 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Starbox Group Holdings Ltd. Announces First Half of Fiscal Year 2023 Financial Results

Source Node:
Time Stamp: August 29, 2023 11:37 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Revenue and Net Profit Increased with Technology Driven Services Revenue Accounted for Approximately 43.8% of its Revenue KUALA LUMPUR, Malaysia, August 29, 2023 / Plato / Amplifi. Starbox Group Holdings Ltd. (Nasdaq: STBX) ("Starbox" or "the Company”), a service provider of cash rebates, digital advertising, and payment solutions with a goal of becoming a comprehensive AI solutions provider within Southeast Asia, today announced its unaudited financial results for the six months ended March 31, 2023. Mr. Lee Choon Wooi, Chairman and Chief Executive Officer of Starbox, commented, “We are excited

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Source Node:
Time Stamp: August 29, 2023 8:16 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

Livento Group, Inc. Announces Second Quarter Results with Revenue Growth of Over 90%, Including Significant Achievements and Updates

Source Node:
Time Stamp: August 17, 2023 3:06 PM - Modified On: August 17, 2023 - Published By:
Source Cluster:
Republished By Plato

NEW YORK, NY / August 14, 2023 / NuGene International, Inc./Livento Group, Inc. (OTC Pink:NUGN), a dynamic leader specializing in the acquisition and development of companies with disruptive business models in film, content, and technology sectors, is pleased to announce revenue growth of 91.65% for the second quarter of 2023, compared to the same period in 2022. Financial Highlights: Revenue Growth:The second quarter ending June 30, 2023, saw revenues of $431,184, up from $224,986 in 2022. For the six-month period ending June 30, 2023, revenues grew from $680,202 to $922,651, a growth of

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:21 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

Crypto Market Trends – BUSD Launched a Crypto Recovery Fund

Source Node:
Time Stamp: April 26, 2023 7:14 AM - Modified On: April 26, 2023 - Published By:
Source Cluster:
Republished By Plato

2023-4-6 The price volatility that has been experienced in the crypto sector since 2022 has shown the need for stablecoin issuers to hedge against their cryptocurrencies to avert potential disastrous eventualities such as implosions. Still, the market has a clear memory of the impact of the Terra USD crash on the crypto market in particular and the digital sector in general. This article discusses Binance’s initiative to introduce a recovery fund for its stablecoin Binance USD (BUSD). Binance to convert the recovery fund into a few cryptocurrencies Recently, Binance announced